Pharmacogenomics firm Gentris Corporation announced this week the appointment of Rick Williams as its CEO and a member of the company's board of directors.
Early in his career, Williams served as Genentech's director of marketing and health economics. Additionally, he has held various executive positons at Merck, Amerisource Bergen, and CellzDirect-Invitrogen. He has also worked with non-profit organizations such as The Hammer Institutes and the North Carolina Biotechnology Center.
Genetic Technologies announced this week the appointment of Lewis Stuart as general manager of its newly established North American molecular diagnostics business. The Melbourne, Australia-based firm is launching a diagnostics unit in the US to expand its genetic testing franchise in oncology with the acquisition of the non-hereditary breast cancer test BREVAGen.
Stuart previously served as the senior VP of commercial operations at CV Therapeutics, which was acquired by Gilead in 2009. Prior to CV Therapeutics, Stuart held senior sales and marketing positions at the Pfizer subsidiary Agouron Pharmaceuticals, Bristol Myers Squibb, Solvay Pharmaceuticals, Centocor, and Upjohn.